Desmopressin Acetate Injection
Function and Efficacy
1. The desmopressin contained in this product is similar in structure to the natural hormone arginine vasopressin. The main difference between it and arginine vasopressin is the deamination of cysteine and the replacement of L-arginine with D-arginine. These structural changes prolong the duration of action of clinical doses of desmopressin without producing the side effect of pressor. 2. Intravenous injection of desmopressin acetate at 0.3 micrograms per kilogram of body weight increases the activity of coagulation factor VIII (VIII:C) in plasma by 2-4 times; this dose also increases von Willebrand antigen factor (vWF:Ag) and releases tissue plasminogen activator (t-PA). 3. For patients with prolonged bleeding time caused by uremia, cirrhosis, congenital or drug-induced platelet dysfunction, and unexplained causes, the bleeding time can be shortened or normalized after administration. 4. The use of this product can avoid the risk of human immunodeficiency virus (HIV) and hepatitis virus infection caused by the use of factor XII preparations.
Ingredients
The main ingredient of this product is desmopressin acetate. Chemical name: 1-Deamino-8-D-arginine vasopressin acetate Chemical structure: Molecular formula: C46H64N14012S2·CH3COOH Molecular weight: 1129.35 Excipients: Sodium chloride, water for injection.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Desmopressin acetateIngredients |
It has a similar structure to the natural hormone arginine vasopressin, but after structural modification, its action time is prolonged and there is no pressor side effect; intravenous injection of 0.3 micrograms per kilogram of body weight can increase the activity of coagulation factor VIII in plasma by 2-4 times, while increasing von Willebrand antigen factor and releasing tissue plasminogen activator; it can be used to shorten or normalize bleeding time; and avoid the risk of HIV and hepatitis virus infection caused by the use of factor XII preparations. More |
16789-98-3 | 18 |
Appearance
This product is a colorless clear liquid.
Indication
Central diabetes insipidus, nocturnal enuresis and hemophilia are also used to test the kidney's urine concentrating function.
Usage and Dosage
Oral administration: diabetes insipidus: 0.1mg-0.2mg/time, 3 times/day; nocturnal enuresis: 0.2mg-0.4mg/time, before bedtime. Intravenous injection: central diabetes insipidus: 1(g-4(g/time for adults, 0.4(g-1(g/time for children over 1 year old, 0.2(g-0.4(g/time for children under 1 year old, 1-2 times/day. Intramuscular or subcutaneous injection: renal urine concentration function test: 4(g for adults, 1(g-2(g for children over 1 year old, 0.4(g for children under 1 year old. Intravenous drip: control bleeding or prevent bleeding before surgery: 0.3(g/kg according to body weight, diluted with normal saline to 50ml-100ml, drip in 15-30min, repeat 1-2 times if necessary.
Adverse Reactions
Fatigue, headache, nausea and stomach pain. Transient hypotension with reflex tachycardia and facial flushing. Dizziness. If water intake is restricted during treatment, water retention may occur with associated symptoms such as decreased blood sodium, weight gain and, in severe cases, convulsions.
Precautions
The following patients are contraindicated to use this product: 1. Patients with habitual and psychogenic polydipsia; 2. Patients with unstable angina; 3. Patients with decompensated heart failure; 4. Patients with type ⅡB von Willebrand disease; 5. Patients with other diseases that require taking diuretics.
Special Population Medication
Precautions for children: Use with caution in young patients. Precautions for pregnancy and lactation: 1. Pregnancy: When rats and rabbits were given desmopressin at a dose that exceeded 100 times the human dose, no teratogenic effect was observed; a researcher reported that three children with malformations had developed when their mothers used desmopressin during pregnancy for diabetes insipidus, but other published case reports of more than 120 cases showed that pregnant women who used desmopressin during pregnancy did not give birth to malformed children; at the same time, a review citing a large amount of data showed that 29 children whose mothers used desmopressin throughout pregnancy did not develop teratogenic phenomena. 2. Lactation: Desmopressin can be secreted into human breast milk, but it is unlikely to have an effect on children when used in therapeutic doses. Precautions for the elderly: Use with caution in elderly patients.
Drug Interactions
1. Some drugs that can cause the release of antidiuretic hormone, such as tricyclic antidepressants, chlorpromazine, carbamazepine, etc., can increase the antidiuretic effect and increase the risk of water retention. 2. Indomethacin (indomethacin) will enhance the patient's response to desmopressin, but will not affect the duration of its effect. This effect may not have any clinical significance.
Storage
Keep tightly closed in a cool, dark and dry place.
Packaging Specification
1ml:4μg
Validity Period
24 months
Manufacturer
Hainan Zhonghe Pharmaceutical Co., Ltd.
-
Founded in:
1995-04-17 -
Address:
No.168 Nanhai Avenue, Haikou City, Haikou Free Trade Zone -
Tax NO.:
91460000293675844T -
Registered Funds:
360 million yuan -
Website:
-
Email: